此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

GZR18注射液CMC变更前后生物等效性研究

2026年11月9日 更新者:Gan & Lee Pharmaceuticals.

一项在健康成年男性受试者中评价CMC变更前后GZR18注射液生物等效性的随机、开放、单剂量、平行对照研究

This is an open-label, randomized, single-dose, parallel comparison bioequivalence study conducted in healthy adult male subjects.

The study is divided into 3 parts, each of which evaluates the bioequivalence of GZR18 Injection for one strength before and after CMC changes.

Subjects eligible for each part of the screening will be randomized into Group A or Group B in a 1:1 ratio. Each subject will receive a single dose of GZR18 Injection, followed by PK blood sampling and safety follow-up for 35 days. Subjects will be admitted to the hospital 1 day predose, follow a standardized light diet that evening, and then fast for at least 10 h thereafter. On the day of administration, GZR18 Injection of a single strength will be administered subcutaneously under fasting conditions at a site approximately two finger-widths (2.5 cm) away from the umbilicus on the abdomen. Lunch and dinner will be served approximately 3 and 9 h postdose, respectively.

Venous blood will be collected at 14 time points for GZR18 plasma concentration analysis: at 0 h (within 60 min predose) and 1, 6, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, and 840 h postdose.

Subjects will undergo corresponding laboratory safety tests at screening, D36, and early withdrawal visits.

During the entire study period, subjects should maintain a light diet, avoid strenuous exercise, and refrain from consuming juice, caffeinated beverages (such as tea and coffee), and alcoholic drinks. Smoking and any other activities that may affect PK observation or safety evaluations are strictly prohibited.

研究概览

研究类型

介入性

注册 (实际的)

266

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Suzhou
      • Suzhou、Suzhou、中国
        • The Second Affiliated Hospital of Soochow University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. Subjects who voluntarily sign the Informed Consent Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol.

  2. Male, 18 to 50 years of age at signing the ICF (both inclusive).

  3. Weight ≥ 50 kg and body mass index (BMI) within 19-26 kg/m2 (inclusive) at screening.

  4. Subjects of childbearing potential with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm donation.

    -

Exclusion Criteria:

  1. Subjects with clinically significant abnormalities detected during the screening period in physical examination, vital signs, laboratory tests, 12-lead ECG, abdominal ultrasound, or chest X-ray, as determined by the investigator.

  2. Subjects who test positive for hepatitis B virus surface antigen, hepatitis C virus IgG antibody, human immunodeficiency virus antibody, P24 antigen, or anti-treponema pallidum antibody.

  3. Subjects with a history of or existing circulatory, urinary, digestive, respiratory, nervous, endocrine, or psychiatric disorders that, in the investigator's judgment, remain clinically significant.

  4. History of acute or chronic pancreatitis and pancreatic injury before screening.

  5. History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2.

  6. Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before randomization.

  7. Subjects with severe infection or unexplained infection within 4 weeks before screening.

  8. Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.

  9. Subjects known or suspected to have hypersensitivity to any ingredient of the investigational medicinal product (IMP) (glucagon like peptide-1 receptor agonist (GLP-1RA) or its excipients).

  10. Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicine within 2 weeks prior to screening; use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists (such as GLP-1R/glucagon receptor [GCGR] agonists or gastric inhibitory polypeptide receptor [GIPR]/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists) within 3 months prior to screening.

  11. Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study.

  12. Blood donation or blood loss greater than or equal to 400 mL within 3 months before screening, or blood donation scheduled during the study or within 8 weeks after the end of the study.

  13. History of drug abuse prior to screening; or positive results for drug abuse at screening (D-1).

  14. History of alcohol abuse within 3 months prior to screening, defined as an average intake of more than 14 units per week (1 standard unit=360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits); or use of any alcohol-containing products 48 hours before administration; or abnormal results for breath alcohol test at screening (D-1).

  15. Subjects who smoked more than 5 cigarettes per day on average within the 3 months before screening, or who do not agree to abstain from smoking for the duration of the study.

  16. Subjects who engage in strenuous exercise within 48 h before administration of the IMP, or have other factors that may affect drug absorption, distribution, metabolism, or excretion.

  17. Subjects who consume grapefruit or grapefruit-containing products, or any caffeinated or xanthine-containing foods or beverages (such as coffee, tea, cola, or chocolate) within 48 hours before administration of the IMP.

  18. Subjects who have special dietary requirements and cannot adhere to a standardized diet, or who are lactose intolerant.

  19. Subjects with a history of needle phobia and blood phobia, difficulty in blood collection or intolerance to venous blood collection.

  20. Subjects who are investigators or employees of the study site, or family members of the employees or investigators.

  21. Participation in a clinical study of another IMP or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP or device before completing all scheduled assessments in the clinical study.

    -

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:GZR18 注射剂 A2

Administered SC

实验性的:GZR18注射液B2

Single dose, s.c.

实验性的:GZR18注射液A3

Administered SC

实验性的:GZR18注射剂B3

Single dose, s.c.

实验性的:GZR18 injection A1

Single dose, s.c.

Administered SC

实验性的:GZR18 injection B1

Single dose, s.c.

Single dose, s.c.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
最大浓度(Cmax)
大体时间:第1天-第36天
第1天-第36天
给药间隔期间浓度-时间曲线下面积(AUC0-t)
大体时间:第1天-第36天
第1天-第36天
从给药时间外推至无穷大的浓度-时间曲线下面积(AUC0-∞)
大体时间:第1天-第36天
第1天-第36天

次要结果测量

结果测量
大体时间
从最后一个时间点外推至无穷大的AUC占AUC0-∞的百分比(AUC_%Extra)
大体时间:第1天-第36天
第1天-第36天
最大观测浓度时间(Tmax)
大体时间:第1天-第36天
第1天-第36天
消除半衰期 (t1/2)
大体时间:第1天-第36天
第1天-第36天
血浆浓度终末相消除速率常数(λz)
大体时间:第1天至第36天
第1天至第36天
治疗期间出现的不良事件 (TEAEs)
大体时间:第1天-第36天
第1天-第36天

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月9日

初级完成 (实际的)

2026年5月22日

研究完成 (实际的)

2026年5月22日

研究注册日期

首次提交

2026年1月5日

首先提交符合 QC 标准的

2026年1月13日

首次发布 (实际的)

2026年1月21日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年1月1日

更多信息

与本研究相关的术语

其他研究编号

  • GZR18-OOO-108

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅